Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Inclusion Criteria

• •Histological confirmation of adenocarcinoma of the breast stage 0-III
• •Evidence of hormone sensitivity with estrogen receptor (ER) and/or progesterone receptor (PR) positive \>= 1% of primary tumor tissue
• •Currently or will be starting on aromatase inhibitor (letrozole, anastrozole, or exemestane)
• •Willingness to self-report vaginal itching, dryness, or dyspareunia
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
• •Obtained =\< 28 days prior to registration: Hemoglobin \>= 8.0 g/dL
• •Obtained =\< 28 days prior to registration: Absolute neutrophil count (ANC) \>= 1500/mm\^3
• •Obtained =\< 28 days prior to registration: Platelet count \>= 75,000/mm\^3
• •Obtained =\< 28 days prior to registration: Total bilirubin =\< 3.0 x upper limit of normal (ULN)
• •Obtained =\< 28 days prior to registration: Aspartate transaminase (AST) =\< 3 x ULN
• •Obtained =\< 28 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =\< 2 x ULN OR if patient is receiving anticoagulant therapy and PT/INR or partial thromboplastin time (PTT) is within therapeutic range of intended use of coagulants
• •Obtained =\< 28 days prior to registration: Calculated creatinine clearance =\< 3 x ULN
• •Recent negative Papanicolaou (PAP) smear within 1 year. In patients who do not have recent PAP smear, PAP smear should be obtained as per standard of care during the screening process prior to enrollment
• •Ability to complete questionnaire(s) by themselves or with assistance
• •Provide written informed consent
• •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)